Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 1
1979 1
1980 2
1981 3
1982 2
1983 1
1984 3
1985 3
1986 4
1987 6
1988 9
1989 6
1990 9
1991 9
1992 14
1993 12
1994 16
1995 11
1996 14
1997 18
1998 21
1999 14
2000 15
2001 21
2002 32
2003 17
2004 25
2005 15
2006 18
2007 16
2008 21
2009 16
2010 14
2011 25
2012 35
2013 36
2014 38
2015 39
2016 38
2017 42
2018 41
2019 43
2020 41
2021 45
2022 30
2023 30
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

785 results

Results by year

Filters applied: . Clear all
Page 1
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM, Tefferi A. Patnaik MM, et al. Am J Hematol. 2022 Mar 1;97(3):352-372. doi: 10.1002/ajh.26455. Epub 2022 Jan 27. Am J Hematol. 2022. PMID: 34985762 Free article. Review.
Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), and the oncogenic RAS pathway (~30%) are frequent, while the presence of ASXL1 and DNMT3A mutations and the absence of TET2 mutations negatively impact overall survival. RISK-STRATIFICATION: Molecularly integrated pr …
Mutations involving TET2 (~60%), SRSF2 (~50%), ASXL1 (~40%), and the oncogenic RAS pathway (~30%) are frequent, while the presence of ASXL1 …
How I diagnose and treat chronic myelomonocytic leukemia.
Patnaik MM. Patnaik MM. Haematologica. 2022 Jul 1;107(7):1503-1517. doi: 10.3324/haematol.2021.279500. Haematologica. 2022. PMID: 35236051 Free PMC article.
The subsequent acquisitions of ASXL1, RUNX1, SF3B1 and DNMT3A mutations usually give rise to dysplastic CMML, while ASXL1, JAK2V617F and RAS pathway mutations give rise to proliferative CMML. Patients with proliferative CMML have a more aggressive course with higher rates …
The subsequent acquisitions of ASXL1, RUNX1, SF3B1 and DNMT3A mutations usually give rise to dysplastic CMML, while ASXL1, JAK2V617F and RAS …
Myelodysplastic/myeloproliferative neoplasms.
Cazzola M, Malcovati L, Invernizzi R. Cazzola M, et al. Hematology Am Soc Hematol Educ Program. 2011;2011:264-72. doi: 10.1182/asheducation-2011.1.264. Hematology Am Soc Hematol Educ Program. 2011. PMID: 22160044 Review.
Recent studies have partly clarified the molecular basis of these disorders, laying the groundwork for the development of molecular diagnostic and prognostic tools. It is hoped that these advances will soon translate into improved therapeutic approaches....
Recent studies have partly clarified the molecular basis of these disorders, laying the groundwork for the development of molecular diagnost …
Chronic myelomonocytic leukemia diagnosis and management.
Chan O, Renneville A, Padron E. Chan O, et al. Leukemia. 2021 Jun;35(6):1552-1562. doi: 10.1038/s41375-021-01207-3. Epub 2021 Mar 13. Leukemia. 2021. PMID: 33714974 Review.
Increased understanding of human monocyte subsets, chromosomal abnormalities, and somatic gene mutations have led to more accurate diagnosis and improved prognostication. A number of risk stratification systems have been developed and validated but using those that incorpo …
Increased understanding of human monocyte subsets, chromosomal abnormalities, and somatic gene mutations have led to more accurate diagnosis …
Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
Jian J, Qiao Y, Li Y, Guo Y, Ma H, Liu B. Jian J, et al. Clin Transl Oncol. 2021 Sep;23(9):1731-1742. doi: 10.1007/s12094-021-02585-x. Epub 2021 Apr 16. Clin Transl Oncol. 2021. PMID: 33861431 Review.
These gene mutations are associated with both the clinical phenotypes and the prognosis of CMML, special CMML variants and pre-phases of CMML. Cytogenetic abnormalities and the size of genome are also associated with prognosis. Meanwhile, cases with ASXL1, DNMT3A, N …
These gene mutations are associated with both the clinical phenotypes and the prognosis of CMML, special CMML variants and pre-phases …
Chronic myelomonocytic leukemia - a review.
Thomopoulos TP, Bouhla A, Papageorgiou SG, Pappa V. Thomopoulos TP, et al. Expert Rev Hematol. 2021 Jan;14(1):59-77. doi: 10.1080/17474086.2021.1860004. Epub 2020 Dec 12. Expert Rev Hematol. 2021. PMID: 33275852 Review.
AREAS COVERED: This review, following a thorough Medline search of pertinent published literature, discusses the diagnostic criteria, the pathogenesis, and the complex genetic landscape of the disease. Prognostication, response criteria, therapeutic management of patients, …
AREAS COVERED: This review, following a thorough Medline search of pertinent published literature, discusses the diagnostic criteria, the pa …
Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia.
Rezazadeh A, Deininger M, Atallah E. Rezazadeh A, et al. Curr Treat Options Oncol. 2023 Aug;24(8):1036-1051. doi: 10.1007/s11864-023-01105-z. Epub 2023 Jun 10. Curr Treat Options Oncol. 2023. PMID: 37300657 Review.
Thus far however, this mechanistic knowledge has not yet been translated into improved outcomes, suggesting that fundamentally new approaches are required. In this review, we discuss the disease course, new classifications, and current treatment landscape of CMML. ...
Thus far however, this mechanistic knowledge has not yet been translated into improved outcomes, suggesting that fundamentally new approache …
Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.
Elmariah H, DeZern AE. Elmariah H, et al. Curr Hematol Malig Rep. 2019 Jun;14(3):154-163. doi: 10.1007/s11899-019-00509-9. Curr Hematol Malig Rep. 2019. PMID: 31093889 Review.
Interest has increased recently in developing tailored approaches for the MDS/MPN overlap syndrome of CMML. RECENT FINDINGS: Multiple prognostic scores have been validated specifically for CMML in the past 5 years. These incorporate somatic mutations, with ASXL1 mutations …
Interest has increased recently in developing tailored approaches for the MDS/MPN overlap syndrome of CMML. RECENT FINDINGS: Multiple pro …
Mouse Models of CMML.
Belotserkovskaya E, Demidov O. Belotserkovskaya E, et al. Int J Mol Sci. 2021 Oct 26;22(21):11510. doi: 10.3390/ijms222111510. Int J Mol Sci. 2021. PMID: 34768940 Free PMC article. Review.
Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortality, associated predominantly with progression to secondary acute myeloid leukemia (sAML), is still an unsolved problem. Despite a growing bo …
Chronic myelomonocytic leukemia (CMML) is a rare and challenging type of myeloproliferative neoplasm. Poor prognosis and high mortali …
Recent Updates on Chronic Myelomonocytic Leukemia.
Loghavi S, Khoury JD. Loghavi S, et al. Curr Hematol Malig Rep. 2018 Dec;13(6):446-454. doi: 10.1007/s11899-018-0475-5. Curr Hematol Malig Rep. 2018. PMID: 30311069 Review.
PURPOSE OF REVIEW: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic …
PURPOSE OF REVIEW: The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic my …
785 results